Molina Healthcare has announced the appointment of Jay Ludlam as the new plan president for Molina Healthcare of Missouri. Ludlam brings extensive experience in healthcare leadership, including previous roles as acting director for MO HealthNet and assistant attorney general for the Medicaid Fraud Control Unit in Missouri, and deputy secretary of Medicaid in North Carolina. His appointment is expected to strengthen Molina's services to Missouri's Medicaid members.

This article details several significant mergers and acquisitions in the advisory sector. Gunderson Capital Management joined GCG Advisory Partners, Pinnacle Wealth Management moved to Ameriprise Financial, Simplicity Group acquired CPS Horizon Financial Group, and OnePoint BFG Wealth Partners acquired Armstrong & Sinoff Financial. These moves highlight consolidation and growth within the financial advisory and wealth management industries, with firms seeking enhanced technology, operational support, and expanded service offerings.

Conagra Brands (NYSE:CAG) Director John Mulligan recently purchased 17,500 shares of company stock for $250,425.00, increasing his total holdings to 20,728 shares. The company also announced a quarterly dividend of $0.35, leading to an annualized yield of 9.9% given the current stock price, despite a negative payout ratio. Conagra's stock currently trades near its 12-month low, and analysts maintain a "Reduce" rating with an average target price of $16.07.

John Laughter, EVP of Delta Air Lines (NYSE:DAL), sold 15,000 shares for $1.07 million, reducing his ownership by 21.62% to 54,369 shares. This sale follows Delta beating Q1 earnings estimates with $0.64 EPS on $14.2 billion revenue, leading analysts to maintain a "Moderate Buy" consensus and raise price targets upwards of $79.26. The stock currently trades around $71.98 with a market cap of $47.29 billion and institutional ownership of nearly 70%.

Lockheed Martin has been awarded two defense contracts totaling $868 million by the U.S. Department of War. The larger contract, valued at $850.4 million, is for the TRIDENT II (D5) Life Extension 2 SSP Alteration Advanced Design and Development Program, with work expected to conclude by September 30, 2030. Additionally, $17.5 million was secured for the F-35 Joint Strike Fighter program to procure material modification kits and special test and tooling equipment, projected to be completed by December 2028.

Kim Bolton, president and portfolio manager at Black Swan Dexteritas, discusses his previous stock selections including Siemens AG, Rockwell Automation, and ABB Ltd, and their current market performance. The article highlights his analysis of these industrial giants within the context of today's market.

Stifel has increased its price target for Chatham Lodging Trust (NYSE:CLDT) from $10.00 to $11.00, maintaining a Buy rating, citing the company's aggressive capital deployment through share repurchases and accretive acquisitions. The firm highlighted CLDT's strong year-to-date performance, outperforming other Lodging REITs, and noted that recent acquisitions are exceeding expectations while Silicon Valley shows recovery in RevPAR. This upgrade follows Chatham Lodging Trust's strong Q4 2025 results, which surpassed earnings expectations, and its strategic acquisition of six hotels.

Celldex Therapeutics' (CLDX) drug Barzolvolimab shows promising rapid, durable, and high complete response rates in urticaria, with Phase III data expected in Q4. The company is well-funded and strategically positioned for both first- and second-line advanced therapy markets, including a promising pipeline drug, CDX-622. This information is based on an H.C. Wainwright conference audio transcript from April 14, 2026.

Alaunos Therapeutics (NASDAQ:TCRT) has received a notice from Nasdaq for non-compliance with its listing rule requiring a minimum of $2.5 million in stockholders’ equity, as the company reported $2.153 million. The company must submit a compliance plan within 45 days and is exploring options to regain compliance, though there's no guarantee of acceptance or successful resolution. Non-compliance could lead to delisting, but Alaunos would have the right to appeal before a Nasdaq hearings panel.

Jana Partners Management, Lp, a director at Lamb Weston (NYSE:LW), recently acquired 100,000 shares of the company's stock for $4,212,000.00, bringing their total ownership to over 5.3 million shares. This purchase was part of a series of acquisitions by Jana Partners in early April, totaling approximately $16.07 million. Despite beating Q1 earnings estimates, Lamb Weston's stock saw a slight decline, and analysts have maintained a "Hold" rating with a consensus price target of $48.00.